Voxmind | $735,203 | (Jun 2, 2026)
Invertix | $1,977,831 | (Jun 2, 2026)
XCENA | $135,000,000 | (Jun 2, 2026)
Certified by Founder
Lodge
Pathalys Pharma
start up
United States
- Raleigh, North Carolina
- 07/02/2023
- Unknown
- $150,000,000
Pathalys Pharma is a private, late-stage clinical biopharmaceutical company committed to the development of advanced therapeutics that address unmet needs in the management of late-stage chronic kidney disease (CKD). Pathalys was created in partnership with Catalys Pacific and DaVita to become a multi-asset pharmaceutical company focused on the needs of patients with end-stage renal disease.
- Industry Biotechnology Research
- Website https://pathalys.com/
- LinkedIn https://www.linkedin.com/company/pathalys/
Inherent | $50,000,000 | (Jun 2, 2026)
Gray Swan | $40,000,000 | (Jun 2, 2026)
Handshake(UK) | $3,200,000 | (Jun 2, 2026)
Sekai(US) | $26,000,000 | (Jun 2, 2026)
Human Archive (YC W26) | $8,200,000 | (Jun 2, 2026)
Perceptic | $12,000,000 | (Jun 2, 2026)
SpeedLabs | $6,500,000 | (Jun 2, 2026)
MokN | $15,000,000 | (May 29, 2026)
Orebella | Undisclosed Amount | (May 29, 2026)